Böhme T, Noory E, Beschorner U, et al. - Researchers assessed the long‐term death following paclitaxel‐coated drug‐eluting stent (DES) angioplasty and use of uncoated devices of femoropopliteal lesions in real world practice. They retrospectively assessed mortality among claudicants Rutherford‐Becker class 1–4 who received DES angioplasty or uncoated balloon or stent angioplasty of femoropopliteal lesions and were observed for 3–7 years. A total of 599 patients were included. For the whole cohort, mortality incidence was 32.3% and 22.6% following uncoated treatment and after DES, respectively. Findings revealed lower long‐term mortality rate following DES angioplasty vs post-treatment with uncoated devices in real world. Co‐morbidities, risk factors, and disease severity were identified as the predictors of mortality.